| Title |
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, November 2014
|
| DOI | 10.1007/s00280-014-2617-3 |
| Pubmed ID | |
| Authors |
Eleonora Marostica, Juthamas Sukbuntherng, David Loury, Jan de Jong, Xavier Woot de Trixhe, An Vermeulen, Giuseppe De Nicolao, Susan O’Brien, John C. Byrd, Ranjana Advani, Jesse McGreivy, Italo Poggesi |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
| Members of the public | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 111 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 109 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 22 | 20% |
| Student > Master | 17 | 15% |
| Other | 14 | 13% |
| Student > Ph. D. Student | 12 | 11% |
| Student > Bachelor | 11 | 10% |
| Other | 16 | 14% |
| Unknown | 19 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 34 | 31% |
| Pharmacology, Toxicology and Pharmaceutical Science | 17 | 15% |
| Agricultural and Biological Sciences | 12 | 11% |
| Biochemistry, Genetics and Molecular Biology | 10 | 9% |
| Nursing and Health Professions | 5 | 5% |
| Other | 13 | 12% |
| Unknown | 20 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 April 2023.
All research outputs
#4,995,457
of 26,017,215 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#244
of 2,608 outputs
Outputs of similar age
#54,240
of 280,244 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#3
of 23 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,608 research outputs from this source. They receive a mean Attention Score of 4.5. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,244 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 86% of its contemporaries.